From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Clinical data
AHFS/Drugs.comInternational Drug Names
Routes of
ATC code
CAS Number
PubChem CID
ECHA InfoCard100.007.537 Edit this at Wikidata
Chemical and physical data
Molar mass608.545 g/mol g·mol−1
3D model (JSmol)
 ☒N☑Y (what is this?)  (verify)

Diosmin (diosmetin 7-O-rutinoside), a flavone derivative also known as venosmine, is a glycoside of diosmetin, which in turn is the 4'-methoxy derivative of luteolin. Diosmin is naturally occurring, mainly in the citrus family rutaceae, but also in herbs such as Teucrium gnaphalodes.[1]


Due to high demand for pharmaceutical use, it is also made semi-synthetically by dehydrogenation of hesperidin, e.g. with iodine in pyridine.[2] Diosmin has 10 stereocenters. It is an oral phlebotropic drug used in the treatment of venous disease, i.e., chronic venous insufficiency (CVI) including spider and varicose veins, leg swelling (edema), stasis dermatitis and venous ulcers. It is also used as a stand-alone or surgical adjunctive therapy in hemorrhoidal disease (HD).

There are extensive clinical trials that show diosmin improves all stages of venous disease including venous ulcers and improves quality of life.[3] There are no prospective studies in arterial disease.

Diosmin is currently a prescription medication in some European countries (tradenames Dio-PP, Venotec, Daflon, Detralex, Vasculera, Arvenum), containing 90% diosmin and 10% hesperidin, and sold as a nutritional supplement in the United States.

Diosmin has been found to be effective in mitigating hyperglycemia in diabetic rats.[4] It is also speculated that diosmin might have potential in the treatment of neurodegenerative diseases,[5] such as Alzheimer's disease, and its anti-inflammatory and anti-apoptotic activity has been demonstrated in neuronal cells, in vitro.[6]


Diosmin prolongs the vasoconstrictor effect of norepinephrine on the vein wall, increasing venous tone, and therefore reducing venous capacitance, distensibility, and venous stasis. This increases the venous return and reduces venous hyperpressure present in patients suffering from CVI.

Diosmin improves lymphatic drainage by increasing the frequency and intensity of lymphatic contractions, and by increasing the total number of functional lymphatic capillaries. Furthermore, diosmin with hesperidine decreases the diameter of lymphatic capillaries and the intralymphatic pressure.

At the microcirculation level, diosmin reduces capillary hyperpermeability and increases capillary resistance by protecting the microcirculation from damaging processes.

Diosmin reduces the expression of endothelial adhesion molecules (ICAM1, VCAM1), and inhibits the adhesion, migration, and activation of leukocytes at the capillary level. This leads to a reduction in the release of inflammatory mediators, principally oxygen free radicals and prostaglandins (PGE2, PGF2a).

Regulatory status[edit]

Diosmin is distributed in the U.S. as a dietary supplement and as a prescription medical food.[7] The FDA concluded that there was inadequate evidence on which to base an expectation of safety.,[8] however, diosmin products have been used in Europe for over 40 years with no safety issues. One company that markets diosmin supplements, Nutratech, has responded that diosmin can reasonably be expected to be safe on the basis of clinical trials, and has a long history of use in Europe. In the U.S., dietary supplements are regulated under Dietary Supplement Health and Education Act of 1994, which does not require proof of efficacy so long as no specific health claims are made. The enhanced version of diosmin, Vasculera, is sold as a medical food product. Under FDA regulation, medical food products must obtain GRAS (generally recognized as safe) status and have scientifically proven efficacy.[9]

See also[edit]


  1. ^ Flavonoid Aglycones and Glycosides from Teucrium gnaphalodes. F. A. T. Barberán, M. I. Gil, F. Tomás, F. Ferreres and A. Arques, J. Nat. Prod., 1985, 48 (5), pages 859–860, doi:10.1021/np50041a040
  2. ^ Studies in Organic Chemistry (1981), 11, 115-119
  3. ^ Jantet, G. (2002-06-01). "Chronic venous insufficiency: worldwide results of the RELIEF study. Reflux assEssment and quaLity of lIfe improvEment with micronized Flavonoids". Angiology. 53 (3): 245–256. ISSN 0003-3197. PMID 12025911.
  4. ^ Leelavinothan Pari, Subramani Srinivasan, Antihyperglycemic effect of diosmin on hepatic key enzymes of carbohydrate metabolism in streptozotocin-nicotinamide-induced diabetic rats, Biomedicine & Pharmacotherapy, Volume 64, Issue 7, September 2010, Pages 477-481.
  5. ^ Sirlak, Mustafa; Akar, A. Ruchan; Eryilmaz, Sadik; Cetinkanat, Elif Kuzgun; Ozcinar, Evren; Kaya, Bulent; Elhan, Atilla Halil; Ozyurda, Umit (2010-01-01). "Micronized purified flavonoid fraction in pretreating CABG patients". Texas Heart Institute Journal. 37 (2): 172–177. ISSN 1526-6702. PMC 2851420. PMID 20401289.
  6. ^ Sanjay L.Dholakiya, Kenza E. Benzeroual, Protective effect of Diosmin on LPS-induced apoptosis in PC12 cells and inhibition of TNF- [alpha] expression, Toxicology in Vitro, In Press, Accepted Manuscript, Available online 6 April 2011.
  7. ^ Public Health Service memorandum, Sept. 13, 2005
  8. ^ New Dietary Ingredients in Dietary Supplements, U. S. Food and Drug Administration Center for Food Safety and Applied Nutrition Office of Nutritional Products, Labeling, and Dietary Supplements February 2001 (Updated September 10, 2001) [1], Memorandum [2]
  9. ^ http://www.fda.gov/Food/GuidanceRegulation/GuidanceDocumentsRegulatoryInformation/ucm054048.htm. Missing or empty |title= (help)